Akeso Inc
4RY
Company Profile
Business description
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China, and also has its presence in USA and Other regions.
Contact
No. 6, Shennong Road
Torch Development Zone
Guangdong Province
Zhongshan528437
CHNT: +86 76089873998
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3,529
Stocks News & Analysis
stocks
Undervalued ASX share searches for cost savings
Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.90 | 10.50 | -0.12% |
| CAC 40 | 8,022.69 | 29.82 | -0.37% |
| DAX 40 | 24,130.14 | 32.51 | -0.13% |
| Dow JONES (US) | 48,057.75 | 497.46 | 1.05% |
| FTSE 100 | 9,655.53 | 13.52 | 0.14% |
| HKSE | 25,692.12 | 151.34 | 0.59% |
| NASDAQ | 23,654.15 | 77.67 | 0.33% |
| Nikkei 225 | 50,532.94 | 69.86 | -0.14% |
| NZX 50 Index | 13,385.26 | 14.20 | 0.11% |
| S&P 500 | 6,886.68 | 46.17 | 0.67% |
| S&P/ASX 200 | 8,622.70 | 8.80 | -0.10% |
| SSE Composite Index | 3,894.15 | 6.34 | -0.16% |